

On-treatment changes of liver stiffness at week 26 compared with baseline in patients with HBV-related compensated cirrhosis

Liver International

38, 1045-1054

DOI: [10.1111/liv.13623](https://doi.org/10.1111/liv.13623)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Liver stiffness measurement predicted liver-related events and all-cause mortality: A systematic review and nonlinear dose-response meta-analysis. <i>Hepatology Communications</i> , 2018, 2, 467-476.	2.0	24
2	Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment. <i>Clinical and Experimental Medicine</i> , 2018, 18, 433-443.	1.9	16
3	Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 708-714.	0.8	2
4	Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 745-757.	1.1	11
5	Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. <i>Cancers</i> , 2019, 11, 425.	1.7	8
6	Chronic hepatitis C virus infection. <i>Medicine (United States)</i> , 2019, 98, e17300.	0.4	4
7	Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-9.	0.5	6
8	Regression of liver fibrosis: evidence and challenges. <i>Chinese Medical Journal</i> , 2020, 133, 1696-1702.	0.9	27
9	Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. <i>Seminars in Liver Disease</i> , 2020, 40, 240-255.	1.8	46
10	Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2582-2591.e6.	2.4	57
11	Predictors for the progression of hepatic cirrhosis to hepatocellular carcinoma under long-term antiviral therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 447-453.	0.8	3
12	Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 584-592.	1.8	51
13	Screening varices in patients with HBV-related cirrhosis on antiviral therapy: Platelet alone or together with LSM. <i>Liver International</i> , 2021, 41, 369-377.	1.9	4
14	Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. <i>Liver International</i> , 2021, 41, 1254-1264.	1.9	28
15	Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2499-2513.	2.4	26
16	The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 467-476.	1.8	2
17	Predictive Nomograms for Clinical Outcomes in Hepatitis B-Related Cirrhosis Patients Receiving Antiviral Therapy. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 2707-2719.	1.1	3
18	Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy. <i>Hepatology International</i> , 2021, 15, 82-92.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Assessing Disease Severity and Prognosis. , 2021, , 173-190.		0
20	Prognosis value of liver stiffness measurements by 2D-SWE in primary HBV-positive hepatocellular carcinoma following radiofrequency ablation. Translational Cancer Research, 2020, 9, 2518-2526.	0.4	3
21	Dynamic monitoring with shear wave elastography predicts outcomes of chronic hepatitis B patients with decompensated cirrhosis. Annals of Translational Medicine, 2021, 9, 0-0.	0.7	3
22	Fibrosis Assessment in Patients with HCV orÂHBV Chronic Infection. , 2020, , 113-121.		0
23	Fibrosis regression following hepatitis C antiviral therapy. World Journal of Hepatology, 2022, 14, 1120-1130.	0.8	5
24	Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints. American Journal of Gastroenterology, 2022, 117, 1444-1453.	0.2	4
25	Management of ACLD After HBV-Suppression and HCV-Cure. , 2022, , 239-252.		0
26	Combined model with acoustic radiation force impulse to rule out high-risk varices in HBV-related cirrhosis with viral suppression. Digestive and Liver Disease, 2023, 55, 1062-1071.	0.4	2